Vertex Pharmaceuticals (VRTX) closed the latest trading day at $402.70, indicating a +0.84% change from the previous session's end. This change outpaced the S&P 500's 0.43% loss on the day. At the ...

Fintel reports that on December 31, 2024, DA Davidson initiated coverage of Vertex (NasdaqGM:VERX) with a Buy recommendation.

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

In September, Vertex filed for Chapter 11 bankruptcy protection and accused Irving, Texas-based Matheson Tri-Gas Inc. of ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along ...

Airborne delivered two mirror support structures for the FYST and SOLAT telescopes, assembling assembling 26,300 components.

Vertex (VERX) has received a new Buy rating, initiated by D.A. Davidson analyst, Will Jellison.Don't Miss Our New Year's Offers:Discover the ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

Of the top news articles, Vertex Pharmaceuticals' suzetrigine garnered much attention as it's a promising new class of pain ...

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

The tower aims to provide new coverage to areas described as "key roadways" by the applicants, including Route 1A, Route 103 ...